Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter.

Cabaletta Bio Stock Performance

CABA opened at $1.79 on Tuesday. The firm has a market cap of $87.49 million, a P/E ratio of -0.83 and a beta of 2.58. Cabaletta Bio has a 52-week low of $1.59 and a 52-week high of $19.06. The business’s fifty day moving average is $2.24 and its 200-day moving average is $3.17.

Wall Street Analysts Forecast Growth

CABA has been the topic of several analyst reports. Evercore ISI lowered Cabaletta Bio from an “outperform” rating to an “inline” rating and reduced their target price for the stock from $15.00 to $6.00 in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research note on Tuesday, February 18th. Wells Fargo & Company lowered Cabaletta Bio from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $12.00 to $6.00 in a research note on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. Finally, TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cabaletta Bio presently has a consensus rating of “Buy” and a consensus target price of $22.71.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.